View Activities

CPD 1: LAN MAT: What You Need to Know - An Overview of Long-acting Naltrexone (LAN)

Activity Details
  • Credit Amounts:
    • CME: 1.00
    • CPE: 1.00
    • Other: 1.00
    • ASWB ACE: 1.00
    • CNE: 1.00
  • Cost: Free
  • Release: Jan 17, 2024
  • Expires: Jan 17, 2027
  • Estimated Time to Complete:
    1 Hour(s)
  • Average User Rating:
    (10 Ratings)

Faculty

Melanie Dicks Melanie Dicks, PharmD
Clinical Assistant Professor, Pharmacy Practice and Science
University of Kentucky College of Pharmacy
Lexington, Kentucky


Needs Statement

Opioid misuse and addiction is a serious national crisis.

  • Affects public health and social and economic welfare.
  • Daily, more than 90 Americans die after overdosing on opioids.

Treatment of opioid dependence is a national priority.

Increasing the knowledge of and accessibility to effective medication-assisted treatments (MATs) for opioid dependence is of utmost importance to address this serious, growing problem.

Health care providers need to be educated and equipped to provide MATs such as long-acting naltrexone in the primary care setting where there is great need for substance use disorder management.

Target Audience

Healthcare professionals in a primary care setting.

Objectives

Upon completion of this educational activity, you will be able to:
1. Identify the evidence supporting use of injectable long-acting naltrexone (LAN) for treatment of opioid use disorder.
2. Describe injectable LAN’s use and place in therapy for the treatment of opioid use disorder.
3. Summarize pertinent patient and provider education for injectable LAN when used for treatment of opioid use disorder.
4. Classify LAN’s role in primary care.

Accreditation

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME
This enduring material is designated for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This training has been approved by the KBML as meeting the statutory requirements of HB1. 0421-H1.0-UK1C

IPE Competencies

  • Roles/ Responsibilities
  • Interprofessional Communication

CPE
This knowledge-based activity will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

Other
UK Healthcare CECentral certifies this activity for 1.00 hour of participation.

ASWB ACE
As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course. Social workers completing this course receive 1.00 clinical continuing education credit.

CNE
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months.  An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

The activity was supported by Anthem.